Pricing Log in Create free account
Saturday 17 October 2026 Export OPK’s income statement to Excel — free account

OPKO Health, Inc.

OPK Healthcare Diagnostics & Research

OPKO Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.9 million, down 14.9% from fiscal 2024. In the quarter to June 2026, revenue grew 4.32%, EPS grew 94.7%, free cash flow grew 46.5% and total debt rose 6.37%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.53 0.08 −4.97%
Market cap
$1.2B
P/E
0.0×
Fwd P/E
−4.7×
Dividend yield
—
F-score
4/9
Altman Z
−0.42
Beneish M
−2.81
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

OPKO Health, Inc. (OPK) Business Profile

Updated before January 2025

Company Overview

OPKO Health, Inc. (NASDAQ: OPK) is a diversified healthcare company that operates in the pharmaceutical, diagnostics, and medical device sectors. Founded in 1991 and headquartered in Miami, Florida, OPKO has grown into a global organization with a strong focus on innovation and patient care. The company was co-founded by Dr. Phillip Frost, a prominent figure in the healthcare industry, who also serves as the Chairman and CEO. Under his leadership, OPKO has pursued strategic acquisitions and partnerships to expand its portfolio and market presence.

Core Business Segments

Pharmaceuticals

OPKO Health’s pharmaceutical division focuses on developing and commercializing proprietary drugs and therapies. Key products include:

  • Rayaldee: A treatment for secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency.
  • Somatrogon: A long-acting human growth hormone developed in collaboration with Pfizer, designed to treat growth hormone deficiency.
  • Varubi: A medication for chemotherapy-induced nausea and vomiting.

Diagnostics

OPKO’s diagnostics segment is anchored by BioReference Laboratories, one of the largest full-service clinical laboratories in the United States. This division provides:

  • Clinical Testing Services: Comprehensive diagnostic testing for physicians, hospitals, and healthcare providers.
  • Genetic Testing: Advanced genetic and genomic testing services for personalized medicine.
  • COVID-19 Testing: During the pandemic, BioReference played a significant role in providing large-scale COVID-19 testing solutions.

Medical Devices

The company also develops and markets innovative medical devices, including:

  • 4Kscore Test: A blood test that assesses the risk of aggressive prostate cancer.
  • Point-of-Care Diagnostics: Devices designed for rapid and accurate diagnostic testing in clinical and non-clinical settings.

Business Model

OPKO Health operates a vertically integrated business model that combines pharmaceuticals, diagnostics, and medical devices to create a comprehensive healthcare ecosystem. The company generates revenue through product sales, diagnostic testing services, and licensing agreements. By leveraging its diverse portfolio, OPKO aims to address unmet medical needs while maintaining a steady revenue stream from multiple sources. Strategic partnerships, such as its collaboration with Pfizer for Somatrogon, further enhance its market reach and financial stability.

Strategic Direction

OPKO Health is committed to driving growth through innovation, strategic acquisitions, and global expansion. Key elements of its strategic direction include:

  • Pipeline Development: Investing in research and development to bring new therapies and diagnostic tools to market.
  • Global Expansion: Strengthening its presence in international markets, particularly in Europe, Latin America, and Asia.
  • Sustainability Goals: Implementing environmentally friendly practices in its operations and supply chain.
  • Digital Transformation: Leveraging technology to enhance diagnostic capabilities and improve patient outcomes.

Competitive Landscape

OPKO Health operates in highly competitive markets, facing competition from both large multinational corporations and specialized healthcare companies. Key competitors include:

  • Pharmaceuticals: Companies like Amgen, Pfizer, and AbbVie.
  • Diagnostics: Quest Diagnostics and Labcorp.
  • Medical Devices: Medtronic and Abbott Laboratories.

Despite the competition, OPKO differentiates itself through its integrated business model and focus on innovation.

Risk Factors

Like any healthcare company, OPKO Health faces several risks, including:

  • Regulatory Challenges: Compliance with stringent FDA and international regulations.
  • Market Dependence: Reliance on the success of key products like Rayaldee and Somatrogon.
  • Supply Chain Disruptions: Vulnerability to global supply chain issues, particularly for raw materials and manufacturing.
  • Competition: Intense competition in the pharmaceutical and diagnostics sectors.
  • Economic Factors: Fluctuations in healthcare spending and reimbursement rates.

Recent Developments

In recent years, OPKO Health has made significant strides in expanding its portfolio and market presence. Notable developments include:

  • FDA Approval of Somatrogon: The long-acting growth hormone received regulatory approval in multiple countries, including the U.S. and Europe.
  • COVID-19 Testing Expansion: BioReference Laboratories played a pivotal role in providing large-scale testing during the pandemic.
  • Strategic Partnerships: Collaborations with companies like Pfizer to co-develop and commercialize new therapies.
  • Acquisitions: The acquisition of smaller biotech firms to enhance its R&D capabilities.

Investment Considerations

Strengths

  • Diverse Portfolio: A broad range of products and services across pharmaceuticals, diagnostics, and medical devices.
  • Innovation: Strong focus on R&D and pipeline development.
  • Strategic Partnerships: Collaborations with industry leaders like Pfizer.
  • Global Reach: Presence in multiple international markets.

Risks

  • Regulatory and Market Risks: Dependence on the success of key products and compliance with regulations.
  • Financial Performance: Fluctuations in revenue and profitability.
  • Competition: Intense competition in all business segments.

Conclusion

OPKO Health, Inc. is a dynamic healthcare company with a diversified portfolio and a strong focus on innovation. While it faces challenges such as regulatory compliance and market competition, its integrated business model and strategic partnerships position it well for future growth. With a commitment to addressing unmet medical needs and expanding its global footprint, OPKO is poised to remain a key player in the healthcare industry.